Radyus Research and Dt&CRO Join Forces to Pave Way for South Korean Biotech Companies into the U.S. Market

ATLANTA, May 7, 2024 /PRNewswire/ — Radyus Research, a global drug development organization from Atlanta, Georgia, is excited to announce a pivotal strategic partnership with Dt&CRO, a leading South Korean contract research organization (CRO). This collaboration aims to assist South Korean biotech companies in entering the U.S. market by offering integrated services for drug development planning, regulatory strategy, IND filings, and clinical trial management.

Dt&CRO company logo
Dt&CRO company logo

The partnership between Radyus Research and Dt&CRO marks a significant milestone in global biotech collaboration, providing a streamlined pathway for South Korean biotech innovators to access the lucrative U.S. pharma market. Leveraging Radyus Research’s expertise in navigating the complex regulatory landscape and managing preclinical and early-stage clinical trials in the United States, South Korean biotech companies can expedite their entry into this key market.

“At Radyus Research, we are thrilled to partner with Dt&CRO to empower their sponsor companies, which are ambitious and innovative biotech companies from South Korea,” said Marta New, CEO of Radyus Research. “Our collaboration will provide invaluable support and guidance, enabling South Korean innovators to navigate regulatory processes, initiate IND applications, and conduct first-in-human trials in the U.S. These critical steps are essential for South Korean biotech companies to establish a strong presence in this market and attract investment from international stakeholders.”

In return, Radyus Research will rely on Dt&CRO for non-GLP and GLP laboratory testing services tailored to Asia based clients. This reciprocal arrangement further enhances the partnership’s synergy, fostering a collaborative environment conducive to innovation and growth in the global biotech industry.

“We are excited to collaborate with Radyus Research to facilitate the expansion of South Korean biotech companies into the U.S. market,” said Mr. Chaegyu Park, CEO of Dt&CRO. “By combining our expertise in laboratory testing with Radyus Research’s comprehensive support for drug development and regulatory strategy, we can offer a holistic solution that meets the needs of biotech innovators in South Korea and enhances our global CRO competitiveness.”

The partnership between Radyus Research and Dt&CRO exemplifies a commitment to fostering innovation, collaboration, and global growth in the biotech industry. Together, they aim to accelerate the development and commercialization of breakthrough therapies that address unmet medical needs and improve patient outcomes worldwide.

About Radyus Research:

Radyus Research is a drug development organization dedicated to accelerating clients’ drug programs into the clinic. With a commitment to excellence and innovation, Radyus Research offers a range of services aimed at providing comprehensive drug development planning, regulatory filings, and clinical trial management. We act as an operating R&D partner to biotech companies, academic startups, and seed venture capital firms. Most clients start working with us during lead optimization and candidate selection phases, and we manage their programs through IND-enabling studies, IND application and initiation of first in human trials. Our extensive expertise spans various modalities in immunology, oncology, infectious diseases, metabolic diseases, and neurosciences. We are based in Atlanta, Georgia, serving clients across the globe in over 12 countries.

About Dt&CRO:

Dt&CRO is a leading preclinical CRO based in South Korea, specializing in providing global pharmaceutical companies with a wide range of CRO services comprehensive of non-clinical efficacy, GLP toxicology testing, PK testing, bioanalysis, bioequivalence, clinical trials, and licensing consultation in Asia. With a commitment to excellence and innovation, as well as its expertise in pharmaceuticals, chemicals, health-functioning food, cosmetics, and medical devices, Dt&CRO plays a vital role in advancing drug development and improving patient care on a global scale.

SOURCE Radyus Research

Georgia’s Life Sciences Momentum is Getting Noticed Nationally.

August 21, 2026
Genetic Engineering & Biotechnology News (GEN) has named Georgia #4 among its “Next 5 States” for emerging U.S. biopharma clusters . The article highlights UCB’s planned $2 billion investment at in Gwinnett County, Micron Biomedical’s new Alpharetta facility, Manus Bio’s expansion in Augusta, Science Square, Emory University, the CDC — and Georgia Life Sciences’ 10-year Life Sciences Roadmap . This recognition is exciting. But even more importantly, it validates the work happening across our entire ecosystem — and perfect momentum as we head into the 2026 Georgia Life Sciences Summit next week. Read more by visiting: Next 10 U.S. Biopharma Clusters

BIO Supports PDUFA VIII Commitment Letter and Urges Timely Reauthorization

August 17, 2026
Biotechnology Innovation Organization (BIO) Senior Vice President of Science & Regulatory Affairs Annetta Beauregard issued the following statement on the release of the Prescription Drug User Fee Act (PDUFA) VIII commitment letter: “For more than 30 years, PDUFA has helped deliver hundreds of new medicines to American patients. As a lead industry negotiator for the PDUFA VIII agreement, BIO supports the PDUFA VIII commitment letter and its strengthening of regulatory review, advancing innovation, and helping deliver safe and effective treatments to patients. “Specifically, the PDUFA VIII agreement includes important commitments that bolster the FDA’s core review activities, ensure accountability for predictable performance, improve financial sustainability and improve communication, transparency and efficiency. “Timely, bipartisan reauthorization of PDUFA is vital for protecting the health of Americans, strengthening U.S. competitiveness, and maintaining America’s global leadership in medical innovation. BIO is committed to working with Congress to ensure reauthorization by September 30, 2027.” The FDA has announced plans to hold a hybrid public meeting at 9am on 9/16 to discuss the proposed enhancements for the reauthorization of PDUFA for fiscal years (FYs) 2028 through 2033. Learn More about PDUFA and the PDUFA VIII commitment letter HERE .

Georgia Life Sciences Submits Comments on Medicare Drug Price Negotiation Program

August 17, 2026
Representing Georgia’s life sciences community, GLS emphasized the importance of advancing policies that improve affordability and patient access while preserving the environment necessary for continued biomedical innovation. In its comments, GLS urged CMS to maintain a framework grounded in FDA regulatory determinations and raised concerns about how certain proposed policies could affect post-approval research and development, investment in new indications, and patient access to innovative therapies. GLS also encouraged CMS to consider the broader implications for healthcare delivery, including the potential impact on patients and providers in rural and underserved communities. As federal drug pricing policy continues to evolve, Georgia Life Sciences will continue to advocate for approaches that balance affordability, access, and innovation while ensuring Georgia’s life sciences community has a voice in the policymaking process. Read Georgia Life Sciences’ full comments to CMS ( click here ).
MORE POSTS